Esperion Therape Stock Price, News & Analysis

Esperion (NASDAQ: ESPR) hosted a virtual R&D Day on November 9, 2022, showcasing discussions on cardiovascular disease treatments by renowned experts. The event highlighted the company’s investigational pipeline, focusing on the CLEAR Outcomes study, which assesses the effectiveness of NEXLETOL in reducing cardiovascular events in statin-intolerant patients. With over 14,000 participants, this Phase 3 trial completed its primary event target in August 2022, positioning Esperion for significant growth in future cardiovascular therapies.

Esperion (NASDAQ: ESPR) announced that President and CEO, Sheldon Koenig, will present at the Jefferies London Healthcare Conference on November 16, 2022, at 5:20 AM (EST). The presentation will include a live audio webcast, accessible via the company's website, with a replay available approximately two hours post-event. Esperion is dedicated to developing innovative medications aimed at lowering cholesterol, especially for patients with unmet needs. For further details, visit www.esperion.com.

Esperion (NASDAQ: ESPR) announced significant developments in its recent press release. The CLEAR Outcomes trial completed its last patient visit in October 2022, with topline results expected in January 2023 and full results in March at the American College of Cardiology event. In Q3 2022, U.S. net product revenue for NEXLETOL® and NEXLIZET® grew by 28% year-over-year to $14.0 million. Overall revenue for Q3 reached $19.0 million, reflecting a 32% increase versus 2021. However, the company reported a net loss of $55.1 million for the quarter.

Esperion (NASDAQ: ESPR) will host a virtual research and development day on November 9, 2022, featuring renowned scientists C. Michael Gibson and Peter Libby. The event will cover Esperion's investigational programs and future growth prospects, including the CLEAR Outcomes trial for bempedoic acid and advancements in its ACLYi platform targeting cardiovascular and metabolic diseases. The trial includes over 14,000 patients and has recorded significant cardiovascular events. This session will provide insights into Esperion's strategic direction and innovative approaches.

Esperion announced the granting of 14,000 restricted stock units (RSUs) to five new employees on October 18, 2022. This action falls under the 2017 Inducement Equity Incentive Plan, aimed at incentivizing individuals who weren't previously associated with the company. The RSUs will vest over four years, with 25% becoming exercisable on the one-year anniversary of their vesting commencement date and the remaining 75% vesting quarterly thereafter, contingent on ongoing employment. Esperion focuses on developing oral LDL-cholesterol lowering medications.

Esperion (NASDAQ: ESPR) is set to announce its third quarter 2022 financial results on November 1, 2022, before U.S. markets open. Following the release, company management will host a webcast at 8:00 a.m. ET to discuss the results and business progress. Interested parties can pre-register for the webcast through their official website, where a replay will also be available approximately two hours after the call, archived for 90 days.

Esperion is focused on developing innovative cholesterol-lowering medications for patients with unmet needs.

Esperion (NASDAQ: ESPR) announced that President and CEO Sheldon Koenig will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 9:20 AM (ET). He will also participate in the H.C. Wainwright Annual Global Investment Conference from September 12-14, 2022, with a presentation scheduled for September 13 at 11:30 AM (ET). Both events will include a presentation format and one-on-one meetings, with webcasts available. Esperion focuses on developing innovative medicines for cholesterol management, including NEXLETOL® and NEXLIZET®.

Esperion (NASDAQ: ESPR) announced that bempedoic acid (NEXLETOL) is now recommended by the American College of Cardiology (ACC) as a vital non-statin therapy for LDL-cholesterol lowering in managing atherosclerotic cardiovascular disease (ASCVD). This update highlights the need for alternative options for patients who cannot achieve LDL-C goals with statins alone. Based on Phase III trial evidence, bempedoic acid has shown a 24.5% reduction in LDL-C levels. The ACC endorsement, along with other recommendations, supports the importance of non-statin therapies in clinical practice.

Esperion (NASDAQ: ESPR) granted 66,000 restricted stock units (RSUs) to 13 new employees on August 2, 2022, through its 2017 Inducement Equity Incentive Plan. This plan targets individuals who were not previous employees or directors, providing inducements for joining Esperion. The RSUs will vest 25% after one year and the remaining 75% in twelve equal quarterly installments, contingent upon continued employment. Esperion specializes in developing oral LDL-cholesterol lowering medications tailored for patients unmet by existing options.